86,750 Shares in Natera, Inc. $NTRA Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new position in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 86,750 shares of the medical research company’s stock, valued at approximately $23,551,000.

A number of other institutional investors and hedge funds have also bought and sold shares of NTRA. BlackRock Inc. bought a new stake in shares of Natera in the 2nd quarter worth approximately $2,962,770,000. Coatue Management LLC grew its holdings in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. Norges Bank purchased a new position in Natera in the 4th quarter worth $372,398,000. Finally, JPMorgan Chase & Co. raised its position in Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on NTRA shares. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Piper Sandler raised their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Robert W. Baird set a $348.00 price objective on Natera in a report on Friday, August 7th. Citigroup boosted their target price on Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Finally, Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the sale, the insider directly owned 129,019 shares in the company, valued at approximately $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 177,955 shares of company stock valued at $40,704,193. 5.05% of the stock is owned by corporate insiders.

Natera Stock Up 0.1%

Shares of NASDAQ NTRA opened at $338.70 on Friday. The firm’s fifty day moving average is $283.17 and its 200 day moving average is $232.96. Natera, Inc. has a 52 week low of $157.43 and a 52 week high of $343.18. The company has a market cap of $48.82 billion, a price-to-earnings ratio of -249.04 and a beta of 1.51.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.74) EPS. Equities research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.